Founded in 2001, Walvax Biotechnology Co., Ltd. is mainly engaged in research and development, manufacture, and distribution of safe, efficacious, and quality vaccines in the world. Headquartered in the southwestern city, Kunming, Yunnan Province, Walvax went IPO in 2010 (300142.SZ) and started business expansion from traditional vaccines into innovative recombinant vaccines.
